Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. Dezember 2025 11:00 ET | Quelle: GT Apeiron LLC

Apeiron Therapeutics Presents First-in-Human Data from Phase 1 Clinical Trial of GTA182 in MTAP-Deleted Advanced Non-Small Cell Lung Cancer at the ESMO Asia Congress 2025

GTA182 demonstrates favorable safety, dose-proportional pharmacokinetics, robust PRMT5 pathway inhibition, and encouraging early antitumor activityIn MTAP-deleted NSCLC, preliminary results show a...
19. November 2024 07:00 ET | Quelle: GT Apeiron LLC

Apeiron Enrolls First Patient in Phase 1a/b Study of PRMT5 Inhibitor GTA182 for MTAP-Deleted Solid Tumors

Apeiron Therapeutics (Apeiron), a precision oncology company leveraging state-of-the-art structural biology and AI-guided molecular modeling for drug disco
17. Oktober 2023 07:00 ET | Quelle: GT Apeiron LLC

GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers

GT Apeiron Therapeutics announces development candidate nomination of GTA182, a brain penetrant MTA-cooperative PRMT5 inhibitor
10. Juli 2023 07:00 ET | Quelle: GT Apeiron LLC

GT Apeiron Announces Enrollment of First Patient in Phase 1/2 “ELUCIDATE” Clinical Trial of CDK7 Inhibitor, GTAEXS617, in Advanced Solid Tumors

- Preclinical data from AI-optimized GTAEXS617 support potential for improved therapeutic index compared to other CDK7 inhibitors under development - - Parallel translational initiative to evaluate...